<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        381-212-18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CANDEZA 8/12.5 mg TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CANDESARTAN CILEXETIL,HYDROCHLOROTHIAZIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        16,12.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        23.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Bluepharma - Industria Farmaceutica, S.A." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Bluepharma - Industria Farmaceutica, S.A.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DA06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The name of your medicine is Candeza Plus. It is used for treating high blood pressure (hypertension) in adult patients. It contains two active ingredients: candesartan cilexetil and hydrochlorothiazide. These work together to lower your blood pressure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Candesartan cilexetil belongs to a group of medicines called angiotensin II receptor antagonists. It makes your blood vessels relax and widen. This helps to lower your blood pressure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hydrochlorothiazide belongs to a group of medicines called diuretics (water tablets). It helps your body to get rid of water and salts like sodium in your urine. This helps to lower your blood pressure.</p><p>Your doctor may prescribe Candeza Plus if your blood pressure has not been properly controlled by candesartan cilexetil or hydrochlorothiazide alone.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Candeza Plus if:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are allergic to candesartan cilexetil or hydrochlorothiazide or any of the other ingredients of this medicine (listed in section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are allergic to sulphonamide medicines. If you are not sure if this applies to you, please ask your doctor.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are more than 3 months pregnant (it is also better to avoid Candeza Plus in early pregnancy &ndash; see pregnancy section).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have severe kidney problems.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have severe liver disease or biliary obstruction (a problem with the drainage of bile from the gallbladder).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have persistently low levels of potassium in your blood.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have persistently high levels of calcium in your blood.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have ever had gout.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have diabetes or renal impairment and taking aliskiren, as Candeza Plus should not be administered with aliskiren in patients with diabetes mellitus or renal impairment.</p><p>If you are not sure if any of these applies to you, talk to your doctor or pharmacist before taking Candeza Plus.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist if:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have diabetes.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have heart, liver or kidney problems.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have recently had a kidney transplant.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are vomiting, have recently had severe vomiting, or have diarrhoea.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have a disease of the adrenal gland called Conn&rsquo;s syndrome (also called primary hyper-aldosteronism).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have ever had a disease called systemic lupus erythematosus (SLE)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have low blood pressure.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have ever had a stroke.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have ever had allergy or asthma.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You must tell your doctor if you think you are (or might become) pregnant.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Candeza Plus is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have kidney problems,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active ingredient hydrochlorothiazide can cause an unusual reaction, resulting in a decrease in vision and eye pain. These could be symptoms of an increase of pressure in your eye and can happen within hours to weeks of taking Candeza Plus. This can lead to permanent vision impairment, if not treated</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have had skin cancer or if you develop an unexpected skin lesion during the treatment. Treatment with hydrochlorothiazide, particularly long-term use with high doses, may increase the risk of some types of skin and lip cancer (non-melanoma skin cancer). Protect your skin from sun exposure and UV rays while taking Candeza Plus.</p><p>Dual blockade of the renin-angiotensin-aldosterone system (RAAS):</p><p>Combination therapy of ACEI (Angiotensin Converting Enzyme inhibitors) and ARB (Angiotensin II Receptor Blocker) drugs may cause an increased risk of hyperkalemia, worsening of the kidney function and hypotension. Therefore, this combination should not be used, especially in patients with kidney problems.</p><p>Your doctor may want to see you more often and do some tests if you have any of these conditions.</p><p>If you are going to have an operation, tell your doctor or dentist that you are taking Candeza Plus. This is because Candeza Plus, when combined with some anaesthetics, may cause a drop in blood pressure.</p><p>Candeza Plus may cause increased sensitivity of the skin to sun.</p><p>&nbsp;</p><p><u>Children and adolescents</u></p><p>There is no experience with the use of Candeza Plus in children (below the age of 18 years). Therefore Candeza Plus should not be given to children.</p><p>&nbsp;</p><p><strong>Other medicines and Candeza Plus</strong></p><p>Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines. Candeza Plus can affect the way some other medicines work and some medicines can have an effect on Candeza Plus. If you are using certain medicines, your doctor may need to do blood tests from time to time.</p><p>In particular, tell your doctor if you are using any of the following medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other medicines to help lower your blood pressure, including beta-blockers, diazoxide and Angiotensin Converting Enzyme (ACE) inhibitors such as enalapril, captopril, lisinopril or ramipril.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen, diclofenac, celecoxib or etoricoxib (medicines to relieve pain and inflammation).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acetyl salicylic acid (if you are taking more than3 g each day) (medicine to relieve pain and inflammation).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Potassium supplements or salt substitutes containing potassium (medicines that increase the amount of potassium in your blood).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Calcium or Vitamin D supplements.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines to lower your cholesterol, such as colestipol or cholestyramine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines for diabetes (tablets or insulin).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines to control your heart beat (anti arrhythmic agents) such as digoxin and beta-blockers.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines that can be affected by potassium blood levels such as some antipsychotic medicines.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heparin (a medicine for thinning the blood).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Water tablets (diuretics).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Laxatives.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Penicillin (an antibiotic).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amphotericin (for the treatment of fungal infections).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lithium (a medicine for mental health problems).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Steroids such as prednisolone.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pituitary hormone (ACTH).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines to treat cancer.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amantadine (for the treatment of Parkinson&rsquo;s disease or for serious infections caused by viruses).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Barbiturates (a type of sedative also used to treat epilepsy).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carbenoxolone (for treatment of oesophageal disease, or oral ulcers).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anticholinergic agents such as atropine and biperiden.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cyclosporine, a medicine used for organ transplant to avoid organ rejection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other medicines that may lead to enhancement of the antihypertensive effect such as baclofen (a medicine for relief of spasticity), amifostin (used in cancer treatment) and some antipsychotic medicines.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aliskiren,</p><p>&nbsp;Dual Renin-Angiotensin-Aldosterone System (RAAS) blockade:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The combination of aliskiren with ARBs (Angiotensin II Receptor Blockers) or ACEIs (Angiotensin Converting Enzyme inhibitors) is contraindicated in patients with diabetes mellitus or renal impairment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dual blockade (e.g. by adding an ACE-inhibitor to an angiotensin II receptor antagonist) should not be used, especially in patients with kidney problems.</p><p>&nbsp;</p><p><strong>Candeza Plus with food, drink and alcohol</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can take Candeza Plus with or without food.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When you are prescribed Candeza Plus, discuss with your doctor before drinking alcohol. Alcohol may make you feel faint or dizzy.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:924px"><tbody><tr><td style="width:920px"><p><u>Pregnancy</u></p><p>You must tell your doctor if you think you are (<u>or might become</u>) pregnant. Your doctor will normally advise you to stop taking Candeza Plus before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Candeza Plus.</p><p>Candeza Plus is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Tell your doctor if you are breast-feeding or about to start breast-feeding. Candeza Plus is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Some people may feel tired or dizzy when taking Candeza Plus. &nbsp;If this happens to you, do not drive or use any tools or machines.</p><p>&nbsp;</p><p><strong>Important information about some of the ingredients of Candeza Plus</strong></p><p>Candeza Plus contains lactose which is a type of sugar. If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. It is important to keep taking Candeza Plus every day.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose of Candeza Plus is one tablet once a day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the tablet with a drink of water.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Try to take the tablet at the same time each day. This will help you to remember to take it.</p><p>&nbsp;</p><p><strong>If you take more Candeza Plus than you should</strong></p><p>If you take more Candeza Plus than prescribed by your doctor, contact a doctor or pharmacist immediately for advice.</p><p>&nbsp;</p><p><strong>If you forget to take Candeza Plus</strong></p><p>Do not take a double dose to make up for a forgotten tablet. Just take the next dose as normal.</p><p>&nbsp;</p><p><strong>If you stop taking Candeza Plus</strong></p><p>If you stop taking Candeza Plus, your blood pressure may increase again. Therefore do not stop taking Candeza Plus without first talking to your doctor.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, healthcare provider or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. It is important that you are aware of what these side effects may be. Some of the side effects of Candeza Plus are caused by candesartan cilexetil and some are caused by hydrochlorothiazide.</p><p>&nbsp;</p><p><strong>Stop taking Candeza &nbsp;Plus and seek medical help immediately if you have any of the following allergic reactions:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulties in breathing, with or without swelling of the face, lips, tongue and/or throat.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the face, lips, tongue and/or throat, which may cause difficulties in swallowing.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe itching of the skin (with raised lumps).</p><p>&nbsp;</p><p>Candeza Plus may cause a reduction in number of white blood cells. Your resistance to infection may be decreased and you may notice tiredness, an infection or a fever. If this happens contact your doctor. Your doctor may occasionally do blood tests to check whether Candeza Plus has had any effect on your blood (agranulocytosis).</p><p>&nbsp;</p><p>Other possible side effects include:</p><p><strong>Common (affects 1 to 10 users in 100)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in blood test results<strong>:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A reduced amount of sodium in your blood. If this is severe then you may notice weakness, lack of energy, or muscle cramps.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An increased or reduced amount of potassium in your blood, especially if you already have kidney problems or heart failure. If this is severe, you may notice tiredness, weakness, irregular heart beat or pins and needles.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An increased amount of cholesterol, sugar or uric acid in your blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sugar in your urine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling dizzy/spinning sensation or weak.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Respiratory infection.</p><p>&nbsp;</p><p><strong>Uncommon (affects less than 1 user in100)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure. This may make you feel faint or dizzy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of appetite, diarrhoea, constipation, stomach irritation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rash, lumpy rash (hives), rash caused by sensitivity to sunlight.</p><p>&nbsp;</p><p><strong>Rare (affects less than 1 user in 1,000)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jaundice (yellowing of the skin or the whites of your eyes). If this happens to you, contact your doctor immediately.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Effects on how your kidneys work, especially if you have kidney problems or heart failure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty in sleeping, depression, being restless.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tingling or prickling in your arms or legs.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blurred vision for a short time.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal heart beat.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breathing difficulties (including lung inflammation and fluid in the lungs).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High temperature (fever).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the pancreas. This causes moderate to severe pain in the stomach.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle cramps.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Damage to blood vessels causing red or purple dots in the skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A reduction in your red or white blood cells or platelets. You may notice tiredness, an infection, fever or easy bruising.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A severe rash, which develops quickly, with blistering or peeling of the skin and possibly blistering in the mouth.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Worsening of existing lupus erythematosus-like reactions or appearance of unusual skin reactions.</p><p>&nbsp;</p><p><strong>Very rare (affects less than 1 user in10,000)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the face, lips, tongue and/or throat.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Back pain, pain in joints and muscles.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in how your liver is working, including inflammation of the liver (hepatitis). You may notice tiredness, yellowing of your skin and the whites of your eyes and flu like symptoms.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea.</p><p>&nbsp;</p><p><strong>Not known (frequency cannot be estimated from the available data)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden short sightedness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden eye pain (acute angle-closure glaucoma).</p><p>-&nbsp; &nbsp; &nbsp;Choroidal effusion, acute myopia and secondary angle-closure glaucoma.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;skin and lip cancer (non-melanoma skin cancer)</p><p>&nbsp;</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30&ordm;C. Store in the original pack.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the carton and blister pack. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or house hold waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active ingredients in Candeza Plus are candesartan cilexetil and hydrochlorothiazide.</p><p>&nbsp;</p><p>Each tablet of Candeza Plus 8/12.5 mg contains 8 mg of candesartan cilexetil and 12.5mg of hydrochlorothiazide.</p><p>Each tablet of Candeza Plus 16/12.5 mg contains16mg of candesartan cilexetil and 12.5mg of hydrochlorothiazide.</p><p>&nbsp;</p><p>The other ingredients are sodium docusate, sodium lauryl sulphate, calcium carmellose, pre-gelatinized maize starch, hydroxypropyl cellulose, lactose monohydrate and magnesium stearate.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Candeza Plus 8/12.5 mg tablets are white, elliptic, biconvex with a score on both sides and marking “CH” and “08” on the same side.
Candeza Plus 16/12.5 mg tablets are white, elliptic, biconvex with a score on both sides and marking “CH” and “16” on the same side.

The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.

Candeza Plus 8/12.5 mg and 16/12.5 mg tablets are supplied in PVC/PVDC-Alu blisters, in pack size 28 tablets/pack.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Manufactured by: &nbsp; &nbsp; &nbsp;</p><p><strong>Bluepharma Ind&uacute;stria </strong>Portugal</p><p>For:</p><p><strong>&nbsp;SPIMACO ADDWAIEH</strong></p><p><strong>&nbsp;</strong></p><p>Marketing Authorization Holder</p><p><strong>SPIMACO</strong></p><p>AlQassim pharmaceutical plant</p><p>Saudi Pharmaceutical Industries &amp;</p><p>Medical Appliance Corporation</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet is approved in April 2020.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">اسم هذا الدواء هو كانديزا بلس. وهو يستخدم لعلاج ارتفاع ضغط الدم عند المرضى البالغين. وهو يحتوى على مادتين فعالتين هما: كانديسارتان سيليكستيل وهيدروكلوروثيازيد. وهما يعملان معاً على خفض ضغط الدم لديك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانديسارتان سيليكستيل هو دواء ينتمى إلى مجموعة من الأدوية التى&nbsp; تسمى مضادات مستقبل أنجيوتنسين-II. هذا الدواء يعمل على إرخاء وتوسيع الأوعية الدموية. مما يساعد على خفض ضغط الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هيدروكلوروثيازيد ينتمى إلى مجموعة من الأدوية التى تعرف باسم مدرات البول ( أقراص الماء). وهو يساعد الجسم على التخلص من الماء والأملاح مثل الصوديوم عبر البول. مما يساعد على خفض ضغط الدم لديك.</p><p dir="RTL">قد يصف لك طبيبك المعالج أقراص كانديزا بلس إذا لم يتم التحكم بشكل صحيح فى ضغط الدم لديك باستخدام كانديسارتان سيليكستيل أو هيدروكلوروثيازيد كل على حدة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تقم بتناول أقراص كانديزا بلس فى الحالات الآتية:</strong></p><ul><li dir="RTL">إذا كنت تعانى من فرط التحسس تجاه مادة كانديسارتان سيليكستيل أو تجاه مادة هيدروكلوروثيازيد أو أى من المكونات الأخرى لأقراص كانديزا بلس (انظر فقرة رقم 6).</li><li dir="RTL">إذا كنت تعانى من فرط التحسس تجاه أدوية السلفوناميدات. فى حالة عدم تأكدك من انطباق ذلك عليك, تواصل مع طبيبك المعالج.</li><li dir="RTL">&nbsp;إذا كنتِ فيما بعد الثلاثة أشهر الأولى من الحمل (من الأفضل أيضاً تجنب تناول أقراص كانديزا بلس فى المرحلة الأولى من الحمل- انظرى فقرة الحمل).</li><li dir="RTL">إذا كنت تعانى من مشاكل حادة بالكلى.</li><li dir="RTL">إذا كنت تعانى من مرض حاد بالكبد أو انسداد بالمرارة (وهى وجود مشكلة في تصريف الصفراء من المرارة).</li><li dir="RTL">إذا كانت لديك مستويات منخفضة باستمرار من البوتاسيوم في الدم.</li><li dir="RTL">إذا كانت لديك مستويات مرتفعة باستمرار من الكالسيوم في الدم.</li><li dir="RTL">إذا كنت تعرضت للإصابة بالنقرس.</li><li dir="RTL">إذا كنت مصاباً بداء السكرى أو لديك قصور فى وظائف الكلى وتتناول عقار أليسكيرين, حيث يمنع استخدام أقراص كانديزا بلس بالتزامن مع أليسكيرين فى حالة المرضى المصابين بالسكرى أو بقصور فى وظائف الكلى.</li></ul><p dir="RTL">فى حالة عدم تأكدك من انطباق أى من الحالات المذكورة أعلاه عليك, تواصل مع طبيبك المعالج أو الصيدلى قبل البدء بتناول أقراص كانديزا بلس.</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تواصل مع طبيبك المعالج أو الصيدلى فى الحالات الآتية:</p><ul><li dir="rtl">إذا كنت مصاباً بمرض السكرى.</li><li dir="rtl">إذا كانت لديك مشاكل بالقلب أو الكبد أو الكلى.</li><li dir="rtl">إذا تعرضت مؤخراً لعملية زرع كلية.</li><li dir="rtl">إذا تعرضت مؤخراً لقئ أو تقيؤ شديد أو إسهال.</li><li dir="rtl">إذا كان لديك مرض بالغدة الكظرية يسمى متلازمة كون (ويسمى أيضاً فرط الألدوستيرون الأساسي).</li><li dir="rtl">إذا تعرضت مسبقاً لمرض يسمى الذئبة الحمامية الجهازية (SLE).</li><li dir="rtl">إذا كان لديك انخفاض في ضغط الدم.</li><li dir="rtl">إذا تعرضت مسبقاً&nbsp; لسكتة دماغية.</li><li dir="rtl">إذا تعرضت مسبقاً للحساسية أو الربو.</li><li dir="rtl">لا ينصح بتناول أقراص كانديزا بلس في مرحلة مبكرة من الحمل, ويجب عدم تناول هذا الدواء إذا كنتِ فيما بعد 3 أشهر من الحمل, لأنه قد يسبب ضرراً جسيماً لطفلك إذا ما تم تناوله في تلك المرحلة (انظرى فقرة الحمل).</li><li dir="rtl">إذا كنت تعانى من مشاكل بالكلى,</li></ul><p>-&nbsp; يمكن أن يسبب هيدروكلوروثيازيد المكون النشط رد فعل غير عادي ، قد يؤدي إلى انخفاض في الرؤية وألم العين. قد تكون هذه أعراض زيادة الضغط في عينك ويمكن أن تحدث في غضون ساعات إلى أسابيع من تناول كانديزا بلس. هذا يمكن أن يؤدي إلى ضعف البصر الدائم ، إذا لم يتم علاجه</p><p>- إذا كنت مصابًا بسرطان الجلد أو إذا كنت تعاني من أعراض جلدية غير متوقعة أثناء العلاج. قد يزيد العلاج باستخدام هيدروكلوروثيازيد ، وخاصة الاستخدام طويل المدى بجرعات عالية ، من خطر الإصابة ببعض أنواع سرطان الجلد والشفاه (سرطان الجلد غير الميلانيني). احمي بشرتك من التعرض لأشعة الشمس والأشعة فوق البنفسجية أثناء تناول كانديزا بلس.</p><p dir="RTL">الانسداد المزدوج لنظام رينين-أنجيوتنسين-ألدوستيرون (RAAS):</p><p dir="RTL">الاستخدام بشكل متزامن لمثبطات الإنزيم المحول لأنجيوتنسين مع مضادات مستقبل أنجيوتنسين-II قد يسبب زيادة فى خطورة ارتفاع مستوى البوتاسيوم بالدم وتدهور فى وظائف الكلى وانخفاض ضغط الدم. لذلك, يجب عدم الجمع بين هذه الأدوية عند الاستخدام خصوصاً فى حالة المرضى المصابين بمشاكل بالكلى.</p><p dir="RTL">قد يرغب طبيبك المعالج فى رؤيتك بشكل متكرر وإجراء بعض الاختبارات فى حالة تعرضك لأى من هذه الحالات.</p><p dir="RTL">إذا كنت بصدد الخضوع لعملية جراحية, أخبر طبيبك المعالج أو طبيب أسنانك أنك تتناول أقراص كانديزا بلس. وذلك لأن كانديزا بلس, عند اقترانه مع بعض المسكنات, قد يسبب انخفاضاً في ضغط الدم. كانديزا بلس قد يزيد من حساسية الجلد تجاه الضوء.</p><p dir="RTL"><u>استخدام هذا الدواء للأطفال والمراهقين:</u></p><p dir="RTL">لا توجد خبرة بشأن استخدام أقراص كانديزا بلس فى حالة الأطفال (الأقل فى العمر من 18 سنة). لذلك يجب عدم استخدام هذا الدواء فى حالة الأطفال.</p><p dir="RTL"><strong>كانديزا بلس والأدوية الأخرى:</strong></p><p dir="RTL">أقراص كانديزا بلس قد تؤثر على طريقة عمل بعض الأدوية الأخرى وقد يكون أيضاً لبعض الأدوية الأخرى تأثير على أقراص كانديزا بلس. عند تناولك لبعض الأدوية قد يحتاج طبيبك المعالج إلى إجراء بعض اختبارات الدم من حين لآخر.</p><p dir="RTL">بشكل خاص, أخبر طبيبك المعالج إذا كنت تتناول أياً من الأدوية الآتية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى تساعد على خفض ضغط الدم لديك, بما فيها حاصرات بيتا, ديازوكسيد ومثبطات الإنزيم المحول لأنجيوتنسين ACE مثل إنالابريل, كابتوبريل, ليسينوبريل أو راميبريل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة للالتهابات غير الستيرويدية (المسكنات)، مثل إيبوبروفين، نابروكسين، ديكلوفيناك، السيليكوكسيب أو إيتوريكوكسيب (أدوية للحد من الألم والالتهابات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أسيتيل حمض الساليسيليك (إذا كنت تتناول أكثر من 3 جرام كل يوم) (دواء لتخفيف الألم والالتهابات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مكملات البوتاسيوم أو بدائل الملح التي تحتوي على البوتاسيوم (وهى أدوية تزيد من كمية البوتاسيوم في الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكالسيوم أو المكملات الغذائية التى تحتوى على فيتامين د.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التى تعمل على خفض مستوى الكوليستيرول مثل كوليستيبول أو كوليستيرامين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج مرض السكر (أقراص أو إنسولين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية للسيطرة على ضربات القلب (أدوية للحد من عدم انتظام نبضات القلب) مثل الديجوكسين وحاصرات بيتا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي يمكن أن تتأثر بمستويات البوتاسيوم في الدم مثل بعض الأدوية المضادة للذهان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهيبارين (دواء لترقق الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص المياه (مدرات البول).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الملينات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البنسلين (مضاد حيوي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمفوتريسين (لعلاج الالتهابات الفطرية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ليثيوم (دواء لمشاكل الصحة العقلية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المنشطات مثل بريدنيزولون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هرمون الغدة النخامية (ACTH).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج السرطان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمانتادين (لعلاج مرض باركنسون أو العدوى الفيروسية الخطيرة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الباربيتورات (وهو نوع من المسكنات تستخدم أيضاً لعلاج الصرع).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كربينوكسولون (لعلاج أمراض المرئ, أو قرح الفم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الكولين مثل أتروبين وبيبيريدين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين, وهو دواء يستخدم لزرع الأعضاء لتجنب رفض العضو.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى التي قد تؤدي إلى زيادة تأثير الحد من ارتفاع ضغط الدم مثل باكلوفين (دواء لتخفيف التشنج), أميفوستين (الذي يستخدم في علاج السرطان) وبعض الأدوية المضادة للذهان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أليسكيرين,</p><p dir="RTL">الانسداد المزدوج لنظام رينين-أنجيوتنسين-ألدوستيرون (RAAS):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمنع الاستخدام بشكل متزامن لعقار أليسكيرين مع مضادات مستقبل أنجيوتنسين II أو مثبطات الإنزيم المحول لأنجيوتنسين فى حالة المرضى المصابين بالسكرى أو بقصور فى وظائف الكلى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمنع الانسداد المزدوج لنظام رينين-أنجيوتنسين-ألدوستيرون (على سبيل المثال بواسطة إضافة مثبطات الإنزيم المحول لأنجيوتنسين إلى مضادات مستقبل أنجيوتنسين II), خصوصاً فى حالة المرضى المصابين بمشاكل بالكلى.</p><p dir="RTL"><strong>تناول أقراص كانديزا بلس مع الطعام والشراب والكحول</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن تناول كانديزا بلس مع أو بدون الطعام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تم وصف أقراص كانديزا بلس لك, تواصل مع طبيبك المعالج قبل تناول الكحول. حيث قد يشعرك الكحول بالدوار أو الإغماء.</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><table border="1" align="right" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p dir="RTL"><u>الحمل</u></p><p dir="RTL">يجب عليكِ إخبار طبيبك المعالج إذا كنتِ تعتقدين بأنكِ (أو قد تصبحين) حاملاً. حيث سيقوم الطبيب بإيقاف تناولك لأقراص كانديزا بلس قبل حدوث الحمل أو حالما تعرفين بحملك وسيقوم بوصف دواء آخر لك بدلاً من كانديزا بلس. حيث لا يوصى باستخدام كانديزا بلس فى المرحلة المبكرة من الحمل, ويجب عدم تناوله فيما بعد الثلاثة أشهر الأولى من الحمل, حيث قد يسبب ضرراً جسيماً للجنين عند استخدامه فى تلك الفترة.</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الرضاعة</u></p><p dir="RTL">أخبرى طبيبك المعالج فى حالة قيامك بإرضاع طفلك طبيعياً أو إذا كنتِ تنوين البدء فى إرضاع طفلك بشكل طبيعى. حيث لا يوصى باستخدام كانديزا بلس من قبل الأمهات المرضعات, وقد يقوم طبيبك المعالج باختيار دواء آخر إذا كنتِ ترغبين فى إرضاع طفلك بشكل طبيعى, خصوصاً إذا كان طفلك حديث الولادة أو مولود قبل أوانه.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">بعض الناس قد يشعرون بالدوار أو التعب عند تناول كانديزا بلس. إذا تعرضت لذلك, لا تقم بقيادة السيارة أو استخدام الآلات.</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات أقراص كانديزا بلس</strong></p><p dir="RTL">يحتوى كانديزا بلس على سكر لاكتوز. إذا تم إخبارك من قبل طبيبك المعالج بعدم تحملك لبعض أنواع السكريات, تواصل مع طبيبك المعالج قبل البدء بتناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قم دائماً بتناول أقراص كانديزا بلس تماماً كما أخبرك طبيبك المعالج. فى حالة عدم تأكدك, تحقق من خلال طبيبك المعالج أو الصيدلى. من الضرورى الحرص على تناول أقراص كانديزا بلس يومياً.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الموصى بها من كانديزا بلس هى قرص واحد مرة واحدة يومياً.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بابتلاع القرص كاملاً مع كوب من الماء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاول أن تتناول القرص الخاص بك فى نفس الموعد يومياً. فقد يساعدك ذلك على تذكر تناول الجرعة.</p><p dir="RTL"><strong>فى حالة تناولك أقراص كانديزا بلس أكثر مما ينبغى</strong></p><p dir="RTL">فى حالة تناولك كانديزا بلس أكثر مما وصفه لك طبيبك المعالج, تواصل فوراً مع طبيبك المعالج أو الصيدلى للمشورة.</p><p dir="RTL"><strong>فى حالة نسيان تناول أقراص كانديزا بلس</strong></p><p dir="RTL">لا تقم بمضاعفة الجرعة لتعويض الجرعة المنسية. فقط قم بتناول الجرعة التالية كما هو معتاد.</p><p dir="RTL"><strong>فى حالة التوقف عن تناول أقراص كانديزا بلس</strong></p><p dir="RTL">عند توقفك عن تناول أقراص كانديزا بلس قد يرتفع ضغط الدم لديك مرة أخرى. لذلك, لا تتوقف عن تناول أقراص كانديزا بلس بدون استشارة طبيبك المعالج أولاً.</p><p dir="RTL">إذا كانت لديك أى أسئلة بشأن استخدام هذه الدواء, اسأل طبيبك المعالج أو الصيدلى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية قد يسبب كانديزا بلس أعراضاً جانبية, وإن لم تكن تحدث لكل من يتناول هذا الدواء. من الضرورى لك معرفة ما هى تلك الأعراض الجانبية المحتمل حدوثها. بعض من الأعراض الجانبية لأقراص كانديزا بلس يرجع سببها إلى مادة كانديسارتان سيليكستيل والبعض الآخر من تلك الأعراض يرجع إلى هيدروكلوروثيازيد.</p><p dir="RTL"><strong>توقف عن تناول أقراص كانديزا بلس وابحث عن المساعدة الطبية فوراً إذا تعرضت لأى من تفاعلات الحساسية الآتية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات في التنفس, مع أو بدون تورم في الوجه أو الشفتين أو اللسان و / أو الحلق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الوجه أو الشفتين أو اللسان و / أو الحلق, مما قد يسبب صعوبات في البلع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة شديدة في الجلد (مع كتل مرتفعة بالجلد).</p><p dir="RTL">قد يسبب كانديزا بلس نقصاً فى عدد خلايا الدم البيضاء. مما قد يقلل من مقاومتك للعدوى وقد تتعرض للتعب أو للعدوى أو الحمى. إذا حدث ذلك, تواصل مع طبيبك المعالج. فقد يلجأ طبيبك المعالج فى بعض الأحيان لإجراء بعض اختبارات الدم للتحقق من أى تأثير لأقراص كانديزا بلس على الدم لديك (ندرة المحببات).</p><p dir="RTL">أعراض جانبية أخرى محتملة الحدوث تشمل:</p><p dir="RTL"><strong>أعراض جانبية شائعة (والتى تصيب من 1 إلى 10 لكل 100 مستخدم لهذا الدواء)</strong></p><ul><li dir="RTL">تغيرات في نتائج فحص الدم:</li></ul><p dir="RTL">- انخفاض مستوى الصوديوم في الدم. إذا كان هذا الانخفاض شديد فقد تلاحظ ضعف, ونقص فى الطاقة, أو تقلصات فى العضلات.</p><p dir="RTL">- زيادة أو نقص فى مستوى البوتاسيوم في الدم, وخاصةً إذا كان لديك بالفعل مشاكل في الكلى أو فشل بالقلب. إذا كان هذا الخلل شديد, فقد تلاحظ تعب, وضعف, وعدم انتظام ضربات القلب أو إحساس بوخز الإبر والدبابيس.</p><p dir="RTL">- زيادة كمية الكوليسترول أو السكر أو حمض اليوريك في الدم.</p><ul><li dir="RTL">وجود سكر في البول.</li><li dir="RTL">شعور بالدوار / الإحساس بدوخة أو ضعف.</li><li dir="RTL">الصداع.</li><li dir="RTL">عدوى الجهاز التنفسي.</li></ul><p dir="RTL"><strong>أعراض جانبية غير شائعة (والتى تصيب أقل من 1 لكل 100 مستخدم لهذا الدواء)</strong></p><ul><li dir="RTL">انخفاض ضغط الدم. مما قد يجعلك تشعر بالدوار أو الاغماء.</li><li dir="RTL">فقدان الشهية, وإسهال, أو إمساك, وتهيج المعدة.</li><li dir="RTL">طفح جلدى, أو طفح الجلد العقدي (الشرى), أو طفح بالجلد سببه الحساسية لآشعة الشمس.</li></ul><p dir="RTL"><strong>أعراض جانبية نادرة (والتى تصيب أقل من 1 لكل 1,000 مستخدم لهذا الدواء)</strong></p><ul><li dir="RTL">اليرقان (اصفرار الجلد أو اصفرار بياض عينيك). إذا كان هذا يحدث لك, اتصل بطبيبك المعالج على الفور.</li><li dir="RTL">تأثيرات على كيفية عمل الكليتين, وخاصةً إذا كان لديك مشاكل في الكلى أو فشل بالقلب.</li><li dir="RTL">صعوبة في النوم, أو اكتئاب, وعدم الراحة.</li><li dir="RTL">إحساس بوخز في ذراعيك أو الساقين.</li><li dir="RTL">عدم وضوح الرؤية لفترة قصيرة.</li><li dir="RTL">خلل فى ضربات القلب.</li><li dir="RTL">صعوبات فى التنفس (بما في ذلك التهاب الرئة ووجود سوائل في الرئتين).</li><li dir="RTL">ارتفاع درجة الحرارة (حمى).</li><li dir="RTL">التهاب البنكرياس. مما يسبب آلاماً متوسطة أو شديدة في المعدة.</li><li dir="RTL">تقلصات فى العضلات.</li><li dir="RTL">تلف بالأوعية الدموية مما يسبب بقع حمراء أو أرجوانية في الجلد.</li><li dir="RTL">انخفاض في عدد خلايا الدم الحمراء أو البيضاء أو الصفائح الدموية. فقد تتعرض إلى التعب, أو العدوى أو الحمى أو الكدمات بشكل أسهل.</li><li dir="RTL">طفح جلدي شديد, والذي يتطور بسرعة, مع ظهور تقرحات أو تقشير بالجلد وربما ظهور تقرحات في الفم.</li><li dir="RTL">تفاقم التفاعلات الشبيهة بمرض الذئبة الحمامية الجهازية أو ظهور تفاعلات غير معتادة بالجلد.</li></ul><p dir="RTL"><strong>أعراض جانبية نادرة جداً (والتى تصيب أقل من 1 لكل 10,000 مستخدم لهذا الدواء)</strong></p><ul><li dir="RTL">تورم في الوجه أو الشفتين أو اللسان و / أو الحلق.</li><li dir="RTL">حكة.</li><li dir="RTL">آلام فى الظهر, وآلام في المفاصل والعضلات.</li><li dir="RTL">تغيرات في كيفية عمل الكبد, بما في ذلك التهاب الكبد (الالتهاب الكبدى). فقد تتعرض إلى التعب, واصفرار الجلد &nbsp;واصفرار بياض عينيك&nbsp; وأعراض تشبه الأنفلونزا.</li><li dir="RTL">السعال.</li><li dir="RTL">الغثيان.</li></ul><p dir="RTL"><strong>أعراض جانبية غير معلومة المعدل (لا يمكن الاستدلال عليها من خلال البيانات المتاحة)</strong></p><ul><li dir="RTL">قصر النظر المفاجئ.</li><li dir="RTL">ألم مفاجئ في العين (المياه الزرقاء).</li><li dir="RTL">انصباب المشيمية وقصر النظر الحاد وزرق انسداد الزاوية الثانوي</li><li dir="RTL">سرطان الجلد والشفاه (سرطان الجلد غير الميلانيني)</li></ul><p dir="RTL">إذا لاحظت أن أي من تلك الأعراض الجانبية أصبح جسيماً, أو إذا لاحظت أى أعراض جانبية لم يتم ذكرها فى هذه النشرة. فضلاً أخبر طبيبك المعالج أو الصيدلى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ هذا الدواء بعيداً عن نظر ومتناول الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحفظ هذه الأقراص فى درجة حرارة أقل من 30 درجة مئوية. تحفظ هذه الأقراص فى عبوتها الأصلية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد انتهاء تاريخ الصلاحية المذكور على العبوة والشريط. علماً بأن تاريخ الصلاحية يشير إلى آخر يوم فى الشهر المذكور.</p><p dir="RTL">يجب عدم التخلص من الأدوية عبر النفايات المنزلية أو عبر مياه الصرف الصحى. اسأل الصيدلى عن كيفية التخلص من الأدوية التى لم تعد بحاجة إليها. هذه التدابير سوف تساعد فى حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادتين الفعالتين هما كانديسارتان سيليكستيل وهيدروكلوروثيازيد.</p><p dir="RTL">يحتوى كل قرص من كانديزا بلس 8/12.5ملجم على 8 ملجم من مادة كانديسارتان سيليكستيل و 12.5 ملجم من مادة هيدروكلوروثيازيد.</p><p dir="RTL">يحتوى كل قرص من كانديزا بلس 16/12.5ملجم على 16 ملجم من مادة كانديسارتان سيليكستيل و 12.5 ملجم من مادة هيدروكلوروثيازيد.</p><p dir="RTL">المكونات الأخرى وهى: دوكوسات الصوديوم, كبريتات لوريل الصوديوم, كارميللوز كالسيوم, نشا, هيدروكسي بروبيل سليلوز, لاكتوز أحادى التميه, ستيرات مغنسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">أقراص كانديزا بلس 8/12.5 ملجم هى أقراص بيضاء, بيضاوية الشكل, &nbsp;ثنائية التحدب, بها علامة &ldquo;CH&rdquo; على أحد الجانبين ورقم &quot;08&quot; على نفس الجانب. قابلة للقسمة من كلا الجانبين.</p><p dir="RTL" style="text-align:right">أقراص كانديزا بلس 16/12.5 ملجم هى أقراص بيضاء, بيضاوية الشكل, &nbsp;ثنائية التحدب, بها علامة &ldquo;CH&rdquo; على أحد الجانبين ورقم &ldquo;16&rdquo; على نفس الجانب. قابلة للقسمة من كلا الجانبين. &nbsp;&nbsp;&nbsp;</p><p dir="RTL" style="text-align:right">الحد الفاصل بالقرص فقط لتسهيل البلع وليس بغرض قسمة القرص إلى جرعتين متساويتين.</p><p dir="RTL" style="text-align:right">أقراص كانديزا بلس 8/12.5 ملجم و 16/12.5 ملجم متوفرة في شرائط &nbsp;PVC / PVDC تحتوي على 28 قرصاً.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">صنع بواسطة:</p><p dir="RTL"><strong>شركة بلوفارما للصناعات الدوائية</strong>.</p><p dir="RTL">البرتغال.</p><p dir="RTL">لصالح<strong>:</strong> <strong>سبيماكو- الدوائية</strong></p><p dir="RTL">مالك الحقوق التسويقية:</p><p dir="RTL"><strong>الدوائية</strong></p><p dir="RTL">مصنع الأدوية بالقصيم</p><p dir="RTL">الشركة السعودية للصناعات الدوائية والمستلزمات الطبية.</p><p dir="RTL">المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت الموافقة على هذه النشرة بتاريخ أبريل 2020 .
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Candeza Plus 8mg/12.5 mg tablets
Candeza Plus 16mg/12.5 mg tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One Candeza Plus 8mg/12.5 mg tablet contains 8 mg candesartan cilexetil and 12.5 mg hydrochlorothiazide.
One Candeza Plus 16mg/12.5 mg tablet contains 16 mg candesartan cilexetil and 12.5 mg hydrochlorothiazide.

Each 8mg/12.5 mg tablet contains 91.06mglactose monohydrate. 
Each 16mg/12.5 mg tablet contains 182.12mglactose monohydrate. 

For a full list of excipients, see 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets
Candeza Plus 8/12.5 tablets are white, elliptic, biconvex with a score on both sides and marking “CH” and “08” on the same side.
Candeza Plus 16/12.5 tablets are white, elliptic, biconvex with a score on both sides and marking “CH” and “16” on the same side.

The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Candeza Plus is indicated for the:</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of essential &nbsp;hypertension in adult patients whose blood pressure is not optimally controlled with candesartan cilexetil or hydrochlorothiazide in monotherapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>P</u><u>osology</u></p><p>&nbsp;</p><p>The recommended dose of Candeza Plus is one tablet once daily.</p><p>Dose titration with the individual components (candesartan cilexetil and hydrochlorothiazide) is recommended. When clinically appropriate a direct change from monotherapy to Candeza Plus may be considered. Dose titration of candesartan cilexetil is recommended when switching from hydrochlorothiazide monotherapy. Candeza Plus may be administered in patients whose blood pressure is not optimally controlled with candesartan cilexetil or hydrochlorothiazide monotherapy or Candeza Plus at lower doses.</p><p>&nbsp;</p><p>Most of the antihypertensive effect is usually attained within 4 weeks of initiation of treatment.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>Elderly population</em></p><p>No initial dose adjustment is necessary in elderly patients.</p><p>&nbsp;</p><p><em>Patients with intravascular volume depletion</em></p><p>Dose titration of candesartan cilexetil is recommended in patients at risk for hypotension, such as patients with possible volume depletion (an initial dose of candesartan cilexetil of 4 mg may be considered in these patients).</p><p><em>&nbsp;</em></p><p><em>P</em><em>atients with renal impairment</em></p><p>Loop diuretics are preferred to thiazides in this population. Dose titration of candesartan cilexetil is recommended in patients with mild to moderate renal impairment (creatinine clearance _ 30 ml/min/1.73 m2 Body Surface Area (BSA)) before treatment with Candeza Plus (the recommended starting dose of candesartan cilexetil is 4 mg in these patients).</p><p>Candeza Plus is contraindicated in patients with severe renal impairment (creatinine clearance &lt; 30 ml/min/1.73 m2 BSA) (see section 4.3).</p><p><em>&nbsp;</em></p><p><em>Patients with hepatic impairment</em></p><p>Dose titration of candesartan cilexetil is recommended in patients with mild to moderate hepatic impairment before treatment with Candeza Plus (the recommended starting dose of candesartan cilexetil is 4 mg in these patients). Candeza Plus is contraindicated in patients with severe hepatic impairment and/or cholestasis (see section 4.3).</p><p><em>&nbsp;</em></p><p><u>Paediatric Population</u></p><p>The safety and efficacy of Candeza Plus in children aged between birth and 18 years have not been established in the treatment of hypertension and heart failure. No data are available.</p><p>&nbsp;</p><p><u>Method of administration </u></p><p>Oral use.</p><p>Candeza Plus should be taken once daily with or without food. The bioavailability of candesartan is not affected by food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any of the excipients listed in section 6.1 or to sulfonamide derived active substances. Hydrochlorothiazide is a sulfonamide derived active substance.
Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
Severe renal impairment (creatinine clearance < 30 ml/min/1.73 m2 BSA).
Severe hepatic impairment and/or cholestasis.
Refractory hypokalaemia and hypercalcaemia.
Gout.
Candeza Plus should not be administered with aliskiren in patients with diabetes mellitus or renal impairment.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Renal impairment</u></em></p><p>Loop diuretics are preferred to thiazides in this population. When Candeza Plus is used in patients with impaired renal function, a periodic monitoring of potassium, creatinine and uric acid levels is recommended.</p><p>&nbsp;</p><p><em><u>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</u></em></p><p>Combination therapy of ACEI and ARB drugs may cause an increased risk of hyperkalemia, worsening of the kidney function and hypotension. Therefore, this combination should not be used, especially in patients with kidney problems.</p><p>&nbsp;</p><p><em><u>&nbsp;Kidney transplantation</u></em></p><p>There is limited clinical evidence regarding Candeza Plus use in patients who have undergone renal transplant.</p><p>&nbsp;</p><p><em><u>Rena</u></em><em><u>l artery stenosis</u></em></p><p>Medicinal products that affect the renin-angiotensin-aldosterone system, including angiotensinII receptor antagonists (AIIRAs), may increase blood urea and serum creatinine in patients with bilateral renal artery stenosis or stenosis of the artery to a solitary kidney.</p><p>&nbsp;</p><p><em><u>Intravascular volume depletion</u></em></p><p>In patients with intravascular volume and/or sodium depletion symptomatic hypotension may occur, as described for other agents acting on the renin-angiotensin-aldosterone system. Therefore, the use of Candeza Plus is not recommended until this condition has been corrected.</p><p>&nbsp;</p><p><em><u>Anaes</u></em><em><u>thesia and surgery</u></em></p><p>Hypotension may occur during anaesthesia and surgery in patients treated with angiotensin II antagonists due to blockade of the renin-angiotensin system. Very rarely ,hypotension maybe severe such that it may warrant the use of intravenous fluids and/or vasopressors.</p><p>&nbsp;</p><p><em><u>Hepatic impairment</u></em></p><p>Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma. There is no clinical experience with Candeza Plus in patients with hepatic impairment.</p><p>&nbsp;</p><p><em><u>Aorti</u></em><em><u>c and mitral valve stenosis (obstructive hypertrophic cardiomyopathy)</u></em></p><p>As with other vasodilators, special caution is indicated in patients suffering from haemodynamically relevant aortic or mitral valve stenosis, or obstructive hypertrophic cardiomyopathy.</p><p>&nbsp;</p><p><em><u>Primary hyperaldosteronism</u></em></p><p>Patients with primary hyperaldosteronism generally will not respond to antihypertensive agents acting through inhibition of the renin-angiotensin-aldosterone system. Therefore the use of Candeza Plus is not recommended in this population.</p><p><em>&nbsp;</em></p><p><em><u>Electrolyte imbalance</u></em></p><p>Periodic determination of serum electrolytes should be performed at appropriate intervals. Thiazides, including hydrochlorothiazide, can cause fluid or electrolyte imbalance (hypercalcaemia, hypokalaemia, hyponatraemia, hypomagnesaemia and hypochloraemic alkalosis).</p><p>&nbsp;</p><p>Thiazide diuretics may decrease the urinary calcium excretion and may cause intermittent and slightly increased serum calcium concentrations. Marked hypercalcaemia may be a sign of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function.</p><p>&nbsp;</p><p>Hydrochlorothiazide dose-dependently increases urinary potassium excretion which may result in hypokalaemia. This effect of hydrochlorothiazide seems to be less evident when combined with candesartan cilexetil. The risk for hypokalaemia may be increased in patients with cirrhosis of the liver, in patients experiencing brisk diuresis, in patients with an inadequate oral intake of electrolytes and in patients receiving concomitant therapy with corticosteroids or adrenocorticotropic hormone (ACTH).</p><p>&nbsp;</p><p>Treatment with candesartan cilexetil may cause hyperkalaemia, especially in the presence of heart failure and/or renal impairment. Concomitant use of Candeza Plus and potassium-sparing diuretics, potassium supplements or salt substitutes or other medicinal products that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum potassium. Monitoring of potassium should be undertaken as appropriate.</p><p>Thiazides have been shown to increase the urinary excretion of magnesium, which may result in hypomagnesaemia.</p><p>&nbsp;</p><p><em><u>Metabolic and endocrine effects</u></em></p><p>Treatment with a thiazide diuretic may impair glucose tolerance. Dose adjustment of anti-diabetic medicinal products, including insulin, may be required. Latent diabetes mellitus may become manifest during thiazide therapy. Increases in cholesterol and triglyceride levels have been associated with thiazide diuretic therapy. At the doses contained in Candeza Plus, only minimal effects were observed. Thiazide diuretics increase serum uric acid concentration and may precipitate gout in susceptible patients.</p><p><em>&nbsp;</em></p><p><em><u>Photosensitivity</u></em></p><p>Cases of photosensitivity reactions have been reported during use of thiazide diuretics (see section 4.8). If a photosensitivity reaction occurs, it is recommended to stop treatment. If re-administration of treatment is essential, it is recommended to protect areas exposed to the sun or to artificial UVA radiation.</p><p>&nbsp;</p><p><em><u>General</u></em></p><p>In patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with medicinal products that affect this system including AIIRAs, has been associated with acute hypotension, azotaemia, oliguria or, rarely, acute renal failure. As with any antihypertensive agent, excessive blood pressure decrease in patients with ischemic heart disease or atherosclerotic cerebrovascular disease could result in a myocardial infarction or stroke.</p><p>Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with such a history.</p><p>Exacerbation or activation of systemic lupus erythematosus has been reported with the use of thiazide diuretics.</p><p>&nbsp;</p><p>The antihypertensive effect of Candeza Plus may be enhanced by other anti-hypertensives.</p><p>&nbsp;</p><p>This medicinal product contains lactose, as an excipient, and patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>&nbsp;</p><p><em><u>Pregnancy</u></em></p><p>AIIRAs should not be initiated during pregnancy. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p><p>&nbsp;</p><p><u>Choroidal effusion</u>, acute myopia and secondary angle-closure glaucoma:</p><p>Sulfonamide or sulfonamide derivative drugs can cause an idiosyncratic reaction resulting in <u>choroidal effusion with visual field defect</u>, transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue drug intake as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.</p><p>&nbsp;</p><p><strong><u>Non-melanoma skin cancer</u></strong></p><p>An increased risk of non-melanoma skin cancer (NMSC) [basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)] with increasing cumulative dose of hydrochlorothiazide (HCTZ) exposure has been observed in two epidemiological studies based on the Danish National Cancer Registry. Photosensitizing actions of HCTZ could act as a possible mechanism for NMSC.</p><p>&nbsp;</p><p>Patients taking HCTZ should be informed of the risk of NMSC and advised to regularly check their skin for any new lesions and promptly report any suspicious skin lesions. Possible preventive measures such as limited exposure to sunlight and UV rays and, in case of exposure, adequate protection should be advised to the patients in order to minimize the risk of skin cancer. Suspicious skin lesions should be promptly examined potentially including histological examinations of biopsies. The use of HCTZ may also need to be reconsidered in patients who have experienced previous NMSC (see also section 4.8).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Compounds which have been investigated in clinical pharmacokinetic studies include hydrochlorothiazide, warfarin, digoxin, oral contraceptives (i.e. ethinylestradiol/levonorgestrel), glibenclamide, nifedipine andenalapril. No clinically significant pharmacokinetic interactions with these medicinal products have been identified.</p><p>&nbsp;</p><p>The potassium depleting effect of hydrochlorothiazide could be expected to be potentiated by other medicinal products associated with potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin, carbenoxolone, penicillin G sodium, salicylic acid derivates, steroids, ACTH).</p><p>&nbsp;</p><p>Concomitant use of Candeza Plus and potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, or other medicinal products (e.g. heparin)may increase potassium levels .Monitoring of potassium should be undertaken as appropriate (see section 4.4).</p><p>&nbsp;</p><p>Diuretic-induced hypokalaemia and hypomagnesaemia predisposes to the potential cardiotoxic effects of digitalis glycosides and antiarrhythmics. Periodic monitoring of serum potassium is recommended when Candeza Plus is administered with such medicinal products, and with the following medicinal products that could induce torsades de pointes:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Class Ia antiarrhythmics (e.g. quinidine, hydroquinidine, disopyramide)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Class III antiarrhythmics (e.g. amiodarone, sotalol, dofetilide, ibutilide)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some antipsychotics (e.g. thioridazine, chlorpromazine, levomepromazine, trifluoperazine, cyamemazine, sulpiride, sultopride, amisulpride, tiapride, pimozide, haloperidol, droperiodol)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Others (e.g. bepridil, cisapride, diphemanil, erythromycin iv, halofantrin, ketanserin, mizolastin, pentamidine, sparfloxacine, terfenadine, vincamine iv)</p><p>&nbsp;</p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors. A similar effect may occur with AIIRAs. Use of candesartan with lithium is not recommended. If the combination proves necessary, careful monitoring of serum lithium levels is recommended.</p><p>&nbsp;</p><p>When AIIRAs are administered simultaneously with non-steroidal anti-inflammatory drugs (NSAIDs) (i.e. selective COX2 inhibitors, acetylsalicylic acid(&gt;3 g/day)and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.</p><p>&nbsp;</p><p>As with ACE inhibitors, concomitant use of AIIRAs and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function. The combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.</p><p>&nbsp;</p><p>The diuretic, natriuretic and antihypertensive effect of hydrochlorothiazide is blunted by NSAIDs.</p><p>The absorption of hydrochlorothiazide is reduced by colestipol or cholestyramine.</p><p>The effect of non-depolarising skeletal muscle relaxants (e.g. tubocurarine) may be potentiated by hydrochlorothiazide.</p><p>Thiazide diuretics may increase serum calcium levels due to decreased excretion. If calcium supplements or Vitamin D must be prescribed, serum calcium levels should be monitored and the dose adjusted accordingly.</p><p>&nbsp;</p><p>The hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by thiazides.</p><p>&nbsp;</p><p>Anticholinergic agents (e.g. atropine, biperiden) may increase the bioavailability of thiazide-type diuretics by decreasing gastrointestinal motility and stomach emptying rate.</p><p>&nbsp;</p><p>Thiazide may increase the risk of adverse effects caused by amantadine.</p><p>&nbsp;</p><p>Thiazides may reduce the renal excretion of cytotoxic medicinal products (e.g. cyclophosphamide, methotrexate) and potentiate their myelosuppressive effects.</p><p>&nbsp;</p><p>Postural hypotension may become aggravated by simultaneous intake of alcohol, barbiturates or anaesthetics.</p><p>&nbsp;</p><p>Treatment with a thiazide diuretic may impair glucose tolerance. Dose adjustment of antidiabetic medicinal products, including insulin, may be required. Metformin should be used with caution because of the risk of lactic acidosis induced by possible functional renal failure linked to hydrochlorothiazide.</p><p>&nbsp;</p><p>Hydrochlorothiazide may cause the arterial response to pressor amines (e.g. adrenaline) to decrease but not enough to exclude a pressor effect.</p><p>&nbsp;</p><p>Hydrochlorothiazide may increase the risk of acute renal insufficiency especially with high doses of iodinated contrast media.</p><p>&nbsp;</p><p>Concomitant treatment with cyclosporine may increase the risk of hyperuricaemia and gout-type complications.</p><p>&nbsp;</p><p>Concomitant treatment with baclofen, amifostin, tricyclic antidepressants or neuroleptics may lead to enhancement of the antihypertensive effect and may induce hypotension.</p><p>&nbsp;</p><p>Dual RAAS blockade</p><p>The combination of aliskiren with ARBs or ACEIs is contraindicated in patients with diabetes mellitus or renal impairment.</p><p>Dual blockade (e.g. by adding an ACE-inhibitor to an angiotensin II receptor antagonist) should not be used, especially in patients with kidney problems.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Pregnancy</u></em></p><p><em>Angiotensin II Receptor Antagonists (AIIRAs):</em></p><table border="1" cellspacing="1" cellpadding="1" style="width:808px"><tbody><tr><td style="width:804px">The use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4). The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy(see sections4.3 and 4.4).</td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p></td></tr></tbody></table><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with AIIRAs, similar risks may exist for this class of drugs. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately and, if appropriate, alternative therapy should be started.</p><p>&nbsp;</p><p>Exposure to AIIRA therapy during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation)and neonatal toxicity(renal failure, hypotension, hyperkalaemia)(see section5.3).</p><p>Should exposure to AIIRA shave occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.</p><p>Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p><em>Hydrochlorothiazide:</em></p><p><em>&nbsp;</em></p><p>There is limited experience with hydrochlorothiazide during pregnancy, especially during the first trimester. Animal studies are insufficient.</p><p>Hydrochlorothiazide crosses the placenta. Based on the pharmacological mechanism of action of hydrochlorothiazide its use during the second and third trimesters may compromise foeto-placental perfusion and may cause foetal and neonatal effects like icterus, disturbance of electrolyte balance and thrombocytopenia.</p><p>Hydrochlorothiazide should not be used for gestational oedema, gestational hypertension or preeclampsia due to the risk of decreased plasma volume and placental hypoperfusion, without a beneficial effect on the course of the disease.</p><p>Hydrochlorothiazide should not be used for essential hypertension in pregnant women except in rare situations where no other treatment could be used.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Lactation</u></em></p><p><em>Angiotensin II Receptor Antagonists (AIIRAs):</em></p><p>Because no information is available regarding the use of Candeza Plus during breast- feeding, Candeza Plus is not recommended and alternative treatments with better established safety profiles during breastfeeding are preferable, especially while nursing a new born or preterm infant.</p><p>&nbsp;</p><p><em>&nbsp;</em></p><p><em>Hydrochlorothiazide:</em></p><p>Hydrochlorothiazide is excreted in human milk in small amounts. Thiazides in high doses causing intense diuresis can inhibit the milk production. The use of Candeza Plus during breast-feeding is not recommended.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of candesartan on the ability to drive and use machines have been performed. However, it should be taken into account that occasionally dizziness or weariness may occur during treatment with Candeza Plus.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In controlled clinical studies with candesartan cilexetil/hydrochlorothiazide adverse reactions were mild and transient. Withdrawals from treatment due to adverse events were similar with candesartan cilexetil/hydrochlorothiazide (2.3-3.3%) and placebo (2.7-4.3%).</p><p>&nbsp;</p><p>In clinical trials with candesartan cilexetil/hydrochlorothiazide, adverse reactions were limited to those that were reported previously with candesartan cilexetil and/or hydrochlorothiazide.</p><p>&nbsp;</p><p>The table below presents adverse reactions with candesartan cilexetil from clinical trials and post marketing experience.</p><p>&nbsp;</p><p>In a pooled analysis of clinical trial data of hypertensive patients, adverse reactions with candesartan cilexetil were defined based on an incidence of adverse events with candesartan cilexetil at least 1% higher than the incidence seen with placebo.</p><p>&nbsp;</p><p>The frequencies used in the tables throughout section 4.8 are: very common (2 1/10), common (2 1/100 to &lt; 1/10), uncommon (2 1/1,000 to &lt; 1/100), rare (2 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000) and not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>In a pooled analysis of clinical trial data of hypertensive patients, adverse reactions with candesartan cilexetil were defined based on an incidence of adverse events with candesartan cilexetil at least 1% higher than the incidence seen with placebo.</p><p>&nbsp;</p><p>The frequencies used in the tables throughout section 4.8 are: very common (2 1/10), common (2 1/100 to &lt; 1/10), uncommon (2 1/1,000 to &lt; 1/100), rare (2 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000) and not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System Organ Class</strong></p></td><td><p><strong>Frequency</strong></p></td><td><p><strong>Undesirable Effect</strong></p></td></tr><tr><td><p>Infections and infestations</p></td><td><p>Common</p></td><td><p>Respiratory infection</p></td></tr><tr><td><p>Metabolism and nutrition disorders</p></td><td><p>Very rare</p></td><td><p>Hyperkalaemia, hyponatraemia</p></td></tr><tr><td><p>Nervous system disorders</p></td><td><p>Common</p></td><td><p>Dizziness/vertigo, headache</p></td></tr><tr><td><p>Respiratory, thoracic and mediastinal disorders</p></td><td><p>Very rare</p></td><td><p>Cough</p></td></tr><tr><td><p>Gastrointestinal disorders</p></td><td><p>Very rare</p></td><td><p>Nausea</p></td></tr><tr><td><p>Hepatobiliary disorders</p></td><td><p>Very rare</p></td><td><p>Increased liver enzymes, abnormal hepatic function orhepatitis</p></td></tr><tr><td><p>Skin and subcutaneous tissue disorders</p></td><td><p>Very rare</p></td><td><p>Angioedema, rash, urticaria, pruritus</p></td></tr><tr><td><p>Musculoskeletal and connective tissue disorders</p></td><td><p>Very rare</p></td><td><p>Back pain, arthralgia, myalgia</p></td></tr><tr><td><p>Renal and urinary disorders</p></td><td><p>Very rare</p></td><td><p>Renal impairment, including renal failure in susceptible patients (see section 4.4)</p></td></tr></tbody></table><p>&nbsp;</p><p>The table below presents adverse reactions with hydrochlorothiazide monotherapy usually with doses of 25 mg or higher.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:673px"><tbody><tr><td><p><strong>System Organ Class</strong></p></td><td><p><strong>Frequency</strong></p></td><td><p><strong>Undesirable Effect</strong></p></td></tr><tr><td><p>Blood and lymphatic system disorders</p></td><td><p>Rare</p></td><td><p>Leukopenia, neutropenia/agranulocytosis, thrombocytopenia, aplastic anaemia, bone marrow depression, haemolytic anaemia</p></td></tr><tr><td><p>Immune system disorders</p></td><td><p>Rare</p></td><td><p>Anaphylactic reactions</p></td></tr><tr><td><p>Metabolism and nutrition disorders</p></td><td><p>Common</p></td><td><p>Hyperglycaemia, hyperuricaemia, electrolyte imbalance(including hyponatraemia and hypokalaemia)</p></td></tr><tr><td><p>Psychiatric disorders</p></td><td><p>Rare</p></td><td><p>Sleep disturbances, depression, restlessness</p></td></tr><tr><td rowspan="2"><p>Nervous system disorders</p></td><td><p>Common</p></td><td><p>Light-headedness, vertigo</p></td></tr><tr><td><p>Rare</p></td><td><p>Paraesthesia</p></td></tr><tr><td rowspan="2"><p>Eye disorders</p></td><td><p>Rare</p></td><td><p>Transient blurred vision</p></td></tr><tr><td><p>Not known</p></td><td><p>Acute myopia, acute angle-closure glaucoma, choroidal effusion</p></td></tr><tr><td><p>Cardiac disorders</p></td><td><p>Rare</p></td><td><p>Cardiac arrhythmias</p></td></tr><tr><td rowspan="2"><p>Vascular disorders</p></td><td><p>Uncommon</p></td><td><p>Postural hypotension</p></td></tr><tr><td><p>Rare</p></td><td><p>Necrotising angiitis (vasculitis, cutaneous vasculitis)</p></td></tr><tr><td><p>Respiratory, thoracic and mediastinal disorders</p></td><td><p>Rare</p></td><td><p>Respiratory distress (including pneumonitis and pulmonary oedema)</p></td></tr><tr><td rowspan="2"><p>Gastrointestinal disorders</p></td><td><p>Uncommon</p></td><td><p>Anorexia, loss of appetite, gastric irritation, diarrhoea, constipation</p></td></tr><tr><td><p>Rare</p></td><td><p>Pancreatitis</p></td></tr><tr><td><p>Hepatobiliary disorders</p></td><td><p>Rare</p></td><td><p>Jaundice (intrahepatic cholestatic jaundice)</p></td></tr><tr><td rowspan="2"><p>Skin and subcutaneous tissue disorders</p></td><td><p>Uncommon</p></td><td><p>Rash, urticaria ,photosensitivity reactions</p></td></tr><tr><td><p>Rare</p></td><td><p>Toxic epidermal necrolysis, cutaneous lupus erythaematosus-like reactions, reactivation of cutaneous lupus erythaematosus</p></td></tr><tr><td><p>Musculoskeletal and connective tissue disorders</p></td><td><p>Rare</p></td><td><p>Muscle spasm</p></td></tr><tr><td rowspan="2"><p>Renal and urinary disorders</p></td><td><p>Common</p></td><td><p>Glycosuria</p></td></tr><tr><td><p>Rare</p></td><td><p>Renal dysfunction and interstitial nephritis</p></td></tr><tr><td rowspan="2"><p>General disorders and administration site conditions</p></td><td><p>Common</p></td><td><p>Weakness</p></td></tr><tr><td><p>Rare</p></td><td><p>Fever</p></td></tr><tr><td rowspan="2"><p>Investigations</p></td><td><p>Common</p></td><td><p>Increases in cholesterol and triglycerides</p></td></tr><tr><td><p>Rare</p></td><td><p>Increases in BUN and serum creatinine</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cases of choroidal effusion with visual field defect have been reported after the use of thiazide and thiazide-like diuretics.</p><p>If cases are to be reported for these substances in the future, the appropriate procedure should be used to update the product information accordingly.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-melanoma skin cancer</p><p>Based on available data from epidemiological studies, cumulative dose-dependent association between HCTZ and NMSC has been observed (see also sections 4.4 and 5.1).</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><u>To report any side effect(s):</u></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:343px"><tbody><tr><td style="vertical-align:top; width:340px"><p style="text-align:center"><strong>To report any side effect(s):</strong></p><p style="text-align:center">The National Pharmacovigilance Centre (NPC):</p><p style="text-align:center">Fax: +966-11-205-7662</p><p style="text-align:center">SFDA Call Center: 19999</p><p style="text-align:center">E-mail: npc.drug@sfda.gov.sa</p><p style="text-align:center">Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p style="text-align:center"><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Symptoms</em></p><p>Based on pharmacological considerations, the main manifestation of an overdose of candesartan cilexetil is likely to be symptomatic hypotension and dizziness. In individual case reports of overdose (of up to 672 mg candesartan cilexetil) patient recovery was uneventful.</p><p>&nbsp;</p><p>The main manifestation of an overdose of hydrochlorothiazide is acute loss of fluid and electrolytes. Symptoms such as dizziness, hypotension, thirst, tachycardia, ventricular arrhythmias, sedation/impairment of consciousness and muscle cramps can also be observed.</p><p>&nbsp;</p><p><em>Management</em></p><p>No specific information is available on the treatment of overdose with Candeza Plus. The following measures are, however, suggested in case of overdose.</p><p>&nbsp;</p><p>When indicated, induction of vomiting or gastric lavage should be considered. If symptomatic hypotension should occur, symptomatic treatment should be instituted and vital signs monitored. The patient should be placed supine with the legs elevated. If this is not sufficient, plasma volume should be increased by infusion of isotonic saline solution.</p><p>Serum electrolyte and acid balance should be checked and corrected, if needed. Sympathomimetic medicinal products may be administered if the above-mentioned measures are not sufficient.</p><p>&nbsp;</p><p>Candesartan cannot be removed by haemodialysis. It is not known to what extent hydrochlorothiazide is removed by haemodialysis.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmaco-therapeutic group: Angiotensin II antagonists + diuretics, ATC code<strong>: </strong>C09DA06</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Angiotensin II is the primary vasoactive hormone of the renin-angiotensin-aldosterone system and plays a role in the pathophysiology of hypertension and other cardiovascular disorders. It also has a role in the pathogenesis of organ hypertrophy and end organ damage. The major physiological effects of angiotensin II, such as vasoconstriction, aldosterone stimulation, regulation of salt and water homeostasis and stimulation of cell growth, are mediated via the type 1 (AT<sub>1</sub>) receptor.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>Candesartan cilexetil is a pro-drug which is rapidly converted to the active drug, candesartan, by ester hydrolysis during absorption from the gastrointestinal tract. Candesartan is an AIIRA, selective for AT1 receptors, with tight binding to and slow dissociation from the receptor. It has no agonist activity.</p><p>&nbsp;</p><p>Candesartan does not influence ACE or other enzyme systems usually associated with the use of ACE inhibitors. Since there is no effect on the degradation of kinins, or on the metabolism of other substances, such as substance P, AIIRAs are unlikely to be associated with cough. In controlled clinical trials comparing candesartan cilexetil with ACE inhibitors, the incidence of cough was lower in patients receiving candesartan cilexetil. Candesartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation. The antagonism of the AT1 receptors results in dose related increases in plasma renin levels, angiotensin I and angiotensin II levels, and a decrease in plasma aldosterone concentration.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>The effects of candesartan cilexetil 8-16 mg (mean dose 12 mg) once daily on cardiovascular morbidity and mortality were evaluated in a randomised clinical trial with 4,937 elderly patients (aged 70-89 years, 21% aged 80 or above) with mild to moderate hypertension followed for a mean of 3.7 years (Study on Cognition and Prognosis in the Elderly). Patients received candesartan or placebo with other antihypertensive treatment added as needed. The blood pressure was reduced from 166/90 to 145/80 mmHg in the candesartan group, and from 167/90 to 149/82 mmHg in the control group. There was no statistically significant difference in the primary endpoint, major cardiovascular events (cardiovascular mortality, non-fatal stroke and non-fatal myocardial infarction). There were 26.7 events per 1000 patient-years in the candesartan group versus 30.0 events per 1000 patient-years in the control group (relative risk0.89, 95% CI 0.75 to 1.06, p=0.19).</p><p>&nbsp;</p><p>Hydrochlorothiazide inhibits the active reabsorption of sodium, mainly in the distal kidney tubules, and promotes the excretion of sodium, chloride and water. The renal excretion of potassium and magnesium increases dose-dependently, while calcium is reabsorbed to a greater extent. Hydrochlorothiazide decreases plasma volume and extracellular fluid and reduces cardiac output and blood pressure. During long-term therapy, reduced peripheral resistance contributes to the blood pressure reduction.</p><p>&nbsp;</p><p>Large clinical studies have shown that long-term treatment with hydrochlorothiazide reduces the risk for cardiovascular morbidity and mortality.</p><p>&nbsp;</p><p>Candesartan and hydrochlorothiazide have additive antihypertensive effects.</p><p>&nbsp;</p><p>In hypertensive patients, Candeza Plus results in a dose-dependent and long-lasting reduction in arterial blood pressure without reflex increase in heart rate. There is no indication of serious or exaggerated first dose hypotension or rebound effect after cessation of treatment. After administration of a single dose of Candeza Plus, onset of the antihypertensive effect generally occurs within 2 hours. With continuous treatment, most of the reduction in blood pressure is attained within four weeks and is sustained during long-term treatment. Candeza Plus once daily provides effective and smooth blood pressure reduction over 24 hours, with little difference between maximum and trough effects during the dosing interval. In a double-blind randomised study, Candeza Plus 16 mg/12.5 mg once daily reduced blood pressure significantly more, and controlled significantly more patients, than the combination losartan/hydrochlorothiazide</p><p>50 mg/12.5 mg once daily.</p><p>&nbsp;</p><p>In double-blind, randomised studies, the incidence of adverse events, especially cough, was lower during treatment with Candeza Plus than during treatment with combinations of ACE inhibitors and hydrochlorothiazide.</p><p>&nbsp;</p><p>In two clinical studies (randomised, double-blind, placebo controlled, parallel group) including 275 and 1524 randomised patients<strong>, </strong>respectively, the candesartan cilexetil/hydrochlorothiazide combinations 32 mg/12.5 mg and 32 mg/25 mg resulted in blood pressure reductions of 22/15 mmHg and 21/14 mmHg, respectively, and were significantly more effective than the respective monocomponents.</p><p>&nbsp;</p><p>In a randomised, double-blind, parallel group clinical study including 1975 randomised patients not optimally controlled on 32 mg candesartan cilexetil once daily, the addition of 12.5 mg or 25 mg hydrochlorothiazide resulted in additional blood pressure reductions. The candesartan cilexetil/hydrochlorothiazide combination 32 mg/25 mg was significantly more effective than the 32 mg/12.5 mg combination, and the overall mean blood pressure reductions were 16/10 mmHg and 13/9 mmHg, respectively.</p><p>&nbsp;</p><p>Candesartan cilexetil/hydrochlorothiazide is similarly effective in patients irrespective of age and gender.</p><p>&nbsp;</p><p>Currently there are no data on the use of candesartan cilexetil/hydrochlorothiazide in patients with renal disease/nephropathy, reduced left ventricular function/congestive heart failure and post myocardial infarction.</p><p>&nbsp;</p><p>Non-melanoma skin cancer</p><p>Based on available data from epidemiological studies, cumulative dose-dependent association between HCTZ and NMSC has been observed. One study included a population comprised of 71,533 cases of BCC and of 8,629 cases of SCC matched to 1,430,833 and 172,462 population controls, respectively. High HCTZ use (&ge;50,000 mg cumulative) was associated with an adjusted OR of 1.29 (95% CI: 1.23-1.35) for BCC and 3.98 (95% CI: 3.68-4.31) for SCC. A clear cumulative dose response relationship was observed for both BCC and SCC. Another study showed a possible association between lip cancer (SCC) and exposure to HCTZ: 633 cases of lip-cancer were matched with 63,067 population controls, using a risk-set sampling strategy. A cumulative dose-response relationship was demonstrated with an adjusted OR 2.1 (95% CI: 1.7-2.6) increasing to OR 3.9 (3.0-4.9) for high use (~25,000 mg) and OR 7.7 (5.7-10.5) for the highest cumulative dose (~100,000 mg) (see also section 4.4).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant administration of candesartan cilexetil and hydrochlorothiazide has no clinically significant effect on the pharmacokinetics of either medicinal product.</p><p>&nbsp;</p><p><em><u>Absorption and distribution</u></em></p><p><em>Candesartan cilexetil</em></p><p>Following oral administration, candesartan cilexetil is converted to the active substance candesartan. The absolute bioavailability of candesartan is approximately 40% after an oral solution of candesartan cilexetil. The relative bioavailability of a tablet formulation of candesartan cilexetil compared with the same oral solution is approximately 34% with very little variability. The mean peak serum concentration (C<strong>max</strong>) is reached 3-4 hours following tablet intake. The candesartan serum concentrations increase linearly with increasing doses in the therapeutic dose range. No gender related differences in the pharmacokinetics of candesartan have been observed. The area under the serum concentration versus time curve (AUC) of candesartan is not significantly affected by food.</p><p>&nbsp;</p><p>Candesartan is highly bound to plasma protein (more than 99%). The apparent volume of distribution of candesartan is 0.1 l/kg.</p><p>&nbsp;</p><p><em>Hydrochlorothiazide</em></p><p>Hydrochlorothiazide is rapidly absorbed from the gastrointestinal tract with an absolute bioavailability of approximately 70%. Concomitant intake of food increases the absorption by approximately 15%. The bioavailability may decrease in patients with cardiac failure and pronounced oedema.</p><p>&nbsp;</p><p>&nbsp;</p><p>The plasma protein binding of hydrochlorothiazide is approximately 60%. The apparent volume of distribution is approximately 0.8 l/kg.</p><p>&nbsp;</p><p><em><u>Biotransformation and elimination</u></em></p><p><em>Candesartan cilexetil</em></p><p>Candesartan is mainly eliminated unchanged via urine and bile and only to a minor extent eliminated by hepatic metabolism (CYP2C9). Available interaction studies indicate no effect on CYP2C9 and CYP3A4. Based on <em>in vitro </em>data, no interaction would be expected to occur <em>in vivo </em>with medicinal products whose metabolism is dependent upon cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4. The terminal half-life (t&frac12;) of candesartan is approximately 9 hours. There is no accumulation following multiple doses. The half-life of candesartan remains unchanged (approximately 9 h) after administration of candesartan cilexetil in combination with hydrochlorothiazide. No additional accumulation of candesartan occurs after repeated doses of the combination compared to monotherapy.</p><p>&nbsp;</p><p>Total plasma clearance of candesartan is about 0.37 ml/min/kg, with a renal clearance of about 0.19 ml/min/kg. The renal elimination of candesartan is both by glomerular filtration and active tubular secretion. Following an oral dose of 14C-labelled candesartan cilexetil, approximately 26% of the dose is excreted in the urine as candesartan and 7% as an inactive metabolite while approximately 56% of the dose is recovered in the faeces as candesartan and 10% as the inactive metabolite.</p><p>&nbsp;</p><p><em>Hydrochlorothiazide</em></p><p>Hydrochlorothiazide is not metabolised and is excreted almost entirely as unchanged drug by glomerular filtration and active tubular secretion. The terminal t&frac12; of hydrochlorothiazide is approximately 8 hours. Approximately 70% of an oral dose is eliminated in the urine within 48 hours. The half-life of hydrochlorothiazide remains unchanged (approximately 8 h) after administration of hydrochlorothiazide in combination with candesartan cilexetil. No additional accumulation of hydrochlorothiazide occurs after repeated doses of the combination compared to monotherapy.</p><p>&nbsp;</p><p><em><u>Pharmacokinetics in special populations</u></em></p><p><em>Candesartan cilexetil</em></p><p>In elderly subjects (over 65 years), Cmax and AUC of candesartan are increased by approximately 50% and 80%, respectively in comparison to young subjects. However, the blood pressure response and the incidence of adverse events are similar after a given dose of Candeza Plus in young and elderly patients (see section 4.2).</p><p>&nbsp;</p><p>In patients with mild to moderate renal impairment, Cmax and AUC of candesartan increased during repeated dosing by approximately 50% and 70%, respectively, but the terminal t&frac12; was not altered, compared to patients with normal renal function. The corresponding changes in patients with severe renal impairment were approximately 50% and 110%, respectively. The terminal t&frac12; of candesartan was approximately doubled in patients with severe renal impairment. The pharmacokinetics in patients undergoing haemodialysis were similar to those in patients with severe renal impairment.</p><p>&nbsp;</p><p>In two studies, both including patients with mild to moderate hepatic impairment, there was an increase in the mean AUC of candesartan of approximately 20% in one study and 80% in the other study (see section 4.2). There is no experience in patients with severe hepatic impairment.</p><p>&nbsp;</p><p><em>Hydrochlorothiazide</em></p><p>The terminal t&frac12; of hydrochlorothiazide is prolonged in patients with renal impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There were no qualitative new toxic findings with the combination compared to that observed for each component. In preclinical safety studies candesartan itself had effects on the kidneys and on red cell parameters at high doses in mice, rats, dogs and monkeys. Candesartan caused a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit). Effects on the kidneys (such as regeneration, dilatation and basophilia in tubules; increased plasma concentrations of urea and creatinine) were induced by candesartan which could be secondary to the hypotensive effect leading to alterations of renal perfusion. Addition of hydrochlorothiazide potentiates the nephrotoxicity of candesartan. Furthermore, candesartan induced hyperplasia/hypertrophy of the juxtaglomerular cells. These changes were considered to be caused by the pharmacological action of candesartan and to be of little clinical relevance.</p><p>&nbsp;</p><p>Foetotoxicity has been observed in late pregnancy with candesartan. The addition of hydrochlorothiazide did not significantly affect the outcome of foetal development studies in rats, mice or rabbits (see section 4.6 Pregnancy and lactation).</p><p>&nbsp;</p><p>Candesartan and hydrochlorothiazide both show genotoxic activity at very high concentrations/doses. Data from <em>in vitro </em>and <em>in vivo </em>genotoxicity testing indicate that candesartan and hydrochlorothiazide are unlikely to exert any mutagenic or clastogenic activity under conditions of clinical use.</p><p>&nbsp;</p><p>There was no evidence that either compound is carcinogenic.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Candeza Plus8 mg / 12,5 mg and 16mg / 12,5 mg tablets:</u></p><p>Docusate sodium</p><p>Sodium Laurilsulfate</p><p>Carmellose calcium</p><p>Pregelatinised maizestarch</p><p>Hydroxypropylcellulose</p><p>Lactose Monohydrate</p><p>Magnesium Stearate</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Candeza Plus 8 mg / 12,5 mg tablets: Blister packages of PVC/PVDC-Alu with 28 tablets.</p><p>Candeza Plus 16 mg / 12,5 mg tablets: Blister packages of PVC/PVDC-Alu with 28 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by:      
 Bluepharma Indústria Portugal
 For:
SPIMACO ADDWAIEH

MARKETING AUTHORISATION HOLDER:                
SPIMACO-ADDWAEIH 
AlQassim pharmaceutical plant

Saudi Pharmaceutical Industries &Medical Appliance Corporation


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                APRIL 2020.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>